Wolfe Research analyst Doug Schenkel raised the price target on Myriad Genetics (NASDAQ: MYGN) to $40.00 (from $30.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE